

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SANDBERG, *et al.*

Serial No.: 10/538,669

Filed: 9 March 2006

For: ANTILYMPHOMA TARGETING AGENTS WITH
EFFECTOR AND AFFINITY FUNCTIONS LINKED BY A
TRIFUNCTIONAL REAGENT

Confirmation No. 6007

Art Unit: 1644

Examiner: Ronald B. Schwadron

Atty. Dckt: 033972.013

RESPONSE TO ELECTION OF SPECIES REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Mail Stop: Amendment

Dear Sir:

This is in response to the Restriction Requirement mailed 19 February 2010, wherein the Examiner required a restriction of claims 1-5, 7-19 and 22, to which the time for response is set to expire 19 March 2010.

The Examiner required an election of species as follows:

- a) one of the antibodies in claim 4
- b) one of the chelators recited in claim 10
- c) biotin or one of the derivatives in claim 12

Applicants hereby elect:

a) rituximab: Of the pending claims, at least claims 1-3, 7-16, 18-19 and 22 are generic, and claims 4, 5 and 17 read thereon.

b) DOTA: Of the pending claims, at least claims 1-9, 12-16, 18-19 and 22 are generic, and claims 10-11 and 17 read thereon.

c) biotin: Of the pending claims, at least claims 1-5, 13-19 and 22 are generic, and claims 1 and 20 also read thereon.

Applicants also reserve the right to pursue any subject matter canceled as a result of this Requirement in a continuing application without prejudice or disclaimer.